

Curriculum Vitae - Koen Deloose, MD

A.Z. St. Blasius
Kroonveldlaan 50
B-9200 Dendermonde
Phone: +32 (0) 52 25 25 17
Fax: +32 (0) 52 25 28 15

Private address :

Hofstraat 188
B-9200 Dendermonde-Appels
Mob: +32 (0) 496 87 70 65
E-mail: koen.deloose@telenet.be

Training

High School:

1983 – 1989 : St-Jozefs' College (Kortrijk), Latin – Mathematics

University:

1989 – 1996 : Catholic University (Louvain), Medicine "*Magna cum Laude*"

Surgical Training:

1996 – 1998 : Sint Niklaas Kliniek Kortrijk
1998 – 2000 : Sint Blasius Hospital Dendermonde
2000 – 2002 : Catholic University Louvain

Vascular Surgery:

2002 : Certificate of Vascular Surgery (Belgian Society of vascular Surgery)

08/2002 : Vascular Surgeon at the AZ St-Blasius in Dendermonde

27/06/2012 : **_ISO 14155:2011**: Clinical Investigation of Medical Devices in Human Subjects – Good Clinical Practice

10/2015 : Head of the Department of Vascular Surgery, AZ Sint Blasius Dendermonde

Memberships

Royal Belgian Society of Surgery
Belgian Association of Surgical Trainees (BAST)
Belgian Group of Endoscopic Surgeons (BGES)
International Society of Endovascular Specialists (ISES)
Royal Belgian Society of Vascular Surgery (BSVS)
European Society for Vascular Surgery (ESVS)

2005 : Founding president of the Belgian Young Flowmasters (BYF) – working group of BSVS

Publications

1. Bosiers M, Peeters P, Vermaercke M, Verbist J, Vercaeren P, De Loose K. *Four- year follow up of Renal Artery Revascularization*. TCT, Poster abstract, 1999.
2. Himpens J, Leman G, Deloose K. *Technique of introducing a large Composite Mesh while performing laparoscopic Incisional Herniorrhaphy*. European Journal of Coelio Surgery, june 2000, 34
3. Peeters P, Bosiers M, Verbist J, Deferm H, Haenen L, Vermaercke M, De Waele J, Deloose K. *Two Year European Experience using a uni-body device (Endologix™) for Endovascular AAA Exclusion*. Endocardiovascular WEB Magazine. Vol. 6, 2, June 2002.
4. Deloose K, Pirenne J, Coosemans W, Aerts R. *Combined Pancreas-Liver Transplantation in patient with Primary Sclerosing Cholangitis and Diabetes Mellitus*. Transplantation, August 2002
5. Bosiers M, Peeters P, Verbist J, Schroë H, Deloose K, Lauwers K, Stockx L. *Belgian experience with Filterwire EX™ in the prevention of embolic events during carotid stenting*. J EVT 2003;10:695-701.
6. Peeters P, Bosiers M, Verbist J, Deloose K. *EVAR Patients with Challenging Iliac Arteries*. Endovascular Today, 2003 May/June;Supplement:16-19.
7. Peeters P, Bosiers M, Verbist J, Deloose K. *Consideraciones técnicas en la reparación endovascular de AAA con arterias ilíacas problemáticas*. Técnicas Endovasculares, 2003 Mayo-Agosto;VI(2):781-786.
8. Deloose K, Bosiers M, Vermaercke M, De Waele J. *Follow-up na een varicectomie*. Medi-Sfeer 2003;196:8-10.
9. Deloose K, Bosiers M, Vermaercke M, De Waele J. *Follow-up na arteriële ingrepen*. Medi-Sfeer 2003;196:11-16.
10. Bosiers M, Peeters P, Deloose K, Verbist J. *Comparison of Cerebral Protection Devices for Carotid Artery Stenting*. Schneider et al: Carotid Interventions (5932-X) 2004;13:173-186.
11. Bosiers M, Peeters P, Deloose K, Verbist J, Sprouse LR. *Which should be the protection device of our dreams for Endovascular Carotid Revascularization?*. Greenhalgh et al: 26th Charing Cross Book: Vascular and Endovascular Challenges 2004;54-68.
12. Peeters P, Bosiers M, Verbist J, Deloose K, Sprouse LR. *Endovascular treatment strategies for Supra-aortic Arterial Occlusive Disease*. Greenhalgh et al: 26th Charing Cross Book: Vascular and Endovascular Challenges 2004;243-257.
13. Bosiers M, Peeters P, Deloose K, Verbist J, Sprouse LR. *Endovascular below-the-knee strategies for limb salvage*. Greenhalgh et al: 26th Charing Cross Book: Vascular and Endovascular Challenges 2004;298-311.
14. Bosiers M, Peeters P, Deloose K, Verbist J, Laird J, Scheinert D, Biamino G. *Excimer Laser Revascularization for Critical Limb Ischemia: Has a solution been found?* Business briefing: global surgery, 2004:1-4.
15. Bosiers M, Peeters P, Verbist J, Deloose K. *CAS using the Wallstent/FilterWire EX/EZ*. Endovascular Today 2004;3(7):35-39.
16. Griffiths H, Peeters P, Verbist J, Bosiers M, Deloose K, Heublein B, Rohde R, Kasese V, Isley C, Di Mario C. *Future device: bioabsorbable stents*. The British Journal of Cardiology 2004;11(3):AIC80-84.
17. Bosiers M, Peeters P, Deloose K, Verbist J, Vinck E, De Meester K. *Techniques and results of balloon angioplasty for BTK-lesions in Critical Limb Ischemia*. Becquemin et al: Controversies and Updates in Vascular Surgery 2005;7:40-45.
18. Bosiers M, Peeters P, Deloose K, Verbist J, Vinck E, De Meester K. *First experience using the Edwards self expanding Life Stent in the SFA indication*. Becquemin et al: Controversies and Updates in Vascular Surgery 2005;7:303-304.
19. Bosiers M, Peeters P, Deloose K, Verbist J, Vinck E, De Meester K. *A new concept in Carotid Artery Stenting: NexStent*. Becquemin et al: Controversies and Updates in Vascular Surgery 2005;7:304-305.

20. Peeters P, Bosiers M, Verbist J, Deloose K, Heublein B. *Preliminary results after application of absorbable metal stents in patients with Critical Limb Ischemia*. J Endovasc Ther 2005;12:1-5.
21. Bosiers M, Peeters P, Deloose K, Verbist J, Sprouse LR. *Selection of treatment for patients with carotid artery disease: medication, carotid endarterectomy, or carotid artery stenting*. Vascular 2005;13(2):1-6.
22. Bosiers M, Peeters P, Deloose K, Verbist J. *Carotid artery stenting: which stent for which lesion*. Vascular 2005;13(4):1-7.
23. Peeters P, Decaluwé H; Verbist J, Deloose K, Bosiers M. *Endovascular treatment of femoropopliteal occlusions (TASC D)*. Greenhalgh et al: 276th Charing Cross Book: Vascular and Endovascular Challenges 2005;478-496.
24. Peeters P, Speybrouck S, Verbist J, Deloose K, Bosiers M. *Endovasculaire behandelingstechnieken voor onderbeensletsels*. Tijdschrift voor Cardiologie 2005;17:11-124.
25. Peeters P, Verbist J, Deloose K, Bosiers M. *Endovascular treatment strategies for supra-aortic arterial occlusive disease*. Journ Cardiovasc Surg (Torino) 2005;46:193-201.
26. Bosiers M, Peeters P, Deloose K, Verbist J, Sievert H, Sugita J, Castriota F, Cremonesi A. *Does Carotid Artery Stenting work on the long run : 5-year results in high-volume centers (ELOCAS Registry)*. Journ Cardiovasc Surg (Torino) 2005;46:241-249.
27. Bosiers M, Deloose K, Verbist J, Peeters P. *First Clinical Application of Absorbable Metal Stents in the Treatment of Critical Limb Ischemia: 12-month results*. Vascular Disease Management 2005;2(4):86-91.
28. Bosiers M, Peeters P, Deloose K, Verbist J, Sievert H, Sugita J, Castriota F, Cremonesi A. *Does carotid artery stenting work on the long run : 5-year results in high volume centers (ELOCAS registry)*. Controversies and updates in vascular surgery 2006;27:135-143.
29. Peeters P, Hart JP, Verbist J, Deloose K, Bosiers M. *Do we have the right stents for femoropopliteal lesions?* Controversies and updates in vascular surgery 2006;36:193-200.
30. Bosiers M, Deloose K, Verbist J, Schroë H, Lauwers G, Lansink W, Peeters P. *Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results*. J Vasc Surg 2006 Feb; 43(2):313-318;discussion 318-319.
31. Peeters P, Bosiers M, Verbist J, Deloose K, Sievert H, Sugita J, Castriota F, Cremonesi A. *Does Carotid Stenting Work in the Long Run ? 5-Year Results of CAS in Major European Centers*. J Endovasc Ther 2006;13(Suppl I):I-1-I-40.
32. Bosiers M, Deloose K, Verbist J, Peeters P. *Review of stents for the carotid artery*. J Cardiovasc Surg (Torino). 2006 Apr;47(2):107-113.
33. Bosiers M, Deloose K, Verbist J, Peeters P. *Endovascular treatment of femoropopliteal TASC D will soon become the treatment of choice*. Greenhalgh et al: 28th Charing Cross Book: More Vascular and Endovascular Controversies 2006; 269-278.
34. Bosiers M, Deloose K, Verbist J, Peeters P. *Percutaneous transluminal angioplasty for treatment of 'below-the-knee' critical limb ischemia: early outcomes following the use of sirolimus-eluting stents*. J Cardiovasc Surg 2006: Apr;47(2):171-176.
35. Bosiers M, Deloose K, Verbist J, Peeters P. *Clinical Application of the Xpert Stent*. Endovascular Today 2006;5(2):24-26.
36. Heerinx C, Peeters P, Verbist J, Deloose K, Bosiers M. *Balloon-expandable, radially reinforced ePTFE relining of SDA after remote endarterectomy*. Journ Cardiovasc Surg (Torino) 2006 Jun; 47(3):279-284.
37. Bosiers M, Hart JP, Deloose K, Verbist J, Peeters P. *Endovascular Therapy as the Primary Approach for Limb Salvage in Patients with Critical Limb Ischemia: Experience with 443 Infrapopliteal Procedures*. Vascular 2006;14:63-69.
38. Bosiers M, Deloose K, Verbist J, Peeters P. *Absorbable Metal Stents*. Endovascular Today 2006;5(7):63-64.
39. Bosiers M, Deloose K, Verbist J, Peeters P. *Stentimplantation im Bereich der Karotisstrombahn in der Verantwortung des Gefässchirurgen*. Gefässchirurgie 2006;11:245-252.
40. Bosiers M, Deloose K, Verbist J, Peeters P. *Will absorbable metal stent technology change our practice?* J Cardiovasc Surg 2006;47:393-397.
41. Peeters P, Verbist J, Deloose K, Bosiers M. *Results with heparin bonded polytetrafluoroethylene grafts for femorodistal bypasses*. J Cardiovasc Surg 2006;47:407-413.
42. Hart JP, Peeters P, Verbist J, Deloose K, Bosiers M. *Do device characteristics impact outcome in carotid artery stenting?* J. Vasc. Surgery. 2006;Oct;44(4):725-30; discussion 730-1.

43. Bosiers M, Deloose K, Verbist J, Peeters P. *Embolic Protection Devices*. J Vasc Endovasc Surg 2006;13:125-30.
44. Bosiers M, Puggioni A, Deloose K, Verbist J, Peeters P. *Endovascular approach for critical limb ischemia patients with below-knee pathology*. Touch Briefings – Interventional Cardiology 2006;54-55.
45. Bosiers M, de Donato G, Deloose K, Verbist J, Peeters P, Castriota F, Cremonesi A, Setacci C. *Does free cell area influence the outcome in carotid artery stenting?* European Journal of Vascular and Endovascular Surgery 2007;33:135-141.
46. Bosiers M, Iyer V, Deloose K, Verbist J, Peeters P. *Flemish experience using the Advanta V12 stent-graft for the treatment of iliac artery occlusive disease*. J Cardiovasc Surg 2007;48(1):7-12.
47. Bosiers M, Deloose K, Verbist J, Peeters P. *CAS: it's all in the approach*. Controversies and updates in vascular surgery 2007;2:2-11.
48. Bosiers M, Deloose K, Verbist J, Peeters P. *Resorbierbare Stents im infrainguinalen Gefäßabschnitt*. Gefäßchirurgie 2007;12:27-32.
49. Peeters P, Verbist J, Deloose K, Bosiers M. *Why EVAR has failed in Belgium*. Endovascular Today 2007;6(3):59-60.
50. Bosiers M, de Donato G, Deloose K, Verbist J, Peeters P, Castriota F, Cremonesi A, Setacci C. *Does free cell area influence the outcome in carotid artery stenting?* Greenhalgh et al: 29th Charing Cross Book: More Vascular and Endovascular Challenges 2007;220-232.
51. Bosiers M, de Donato G, Deloose K, Verbist J, Peeters P, Castriota F, Cremonesi A, Setacci C. *Are there predictive risk factors for complications after carotid artery stenting?* J Cardiovasc Surg 2007;48(2):125-130.
52. Bosiers M, Deloose K, Verbist J, Peeters P. *Nitinol stenting for treatment of "below-the-knee" critical limb ischemia: 1-year angiographic outcome after Xpert stent implantation*. J Cardiovasc Surg (Torino). 2007 Aug;48(4):455-61.
53. Iyer V, de Donato G, Deloose K, Peeters P, Castriota F, Cremonesi A, Setacci C, Bosiers M. *The type of embolic protection does not influence the outcome in carotid artery stenting*. J Vasc Surg. 2007 Aug;46(2):251-6.
54. Bosiers M, Kallakuri S, Deloose K, Verbist J, Peeters P. *Infragenicular angioplasty and stenting in the management of critical limb ischemia: one year outcome following the use of the MULTI-LINK VISION stent*. EuroIntervention 2007;3:470-474.
55. Bosiers M, Deloose K, Verbist J, Peeters P, Castriota F, Cremonesi A, Setacci C. *Tibial Occlusive Disease*. Thompson et al: Endovascular Intervention for Vascular Disease 2007;31-39.
56. Bosiers M, Deloose K, Verbist J, Peeters P. *CAS: it's all in the approach*. Controversies and updates in vascular surgery 2008;9:48-53.
57. Puggioni A, Boesman E, Bosiers M, Deloose K, Verbist J, Peeters P, Bosiers M. *Use of StarClose for Brachial Artery Closure after Percutaneous Endovascular Interventions*. Vascular 2008 Mar-Apr;16(2):85-90.
58. Peeters P, Verbist J, Deloose K, Bosiers M. *The Catheterization Lab of the Future*. Endovascular Today 2008;7(3):94-96.
59. Bosiers M, Deloose K, Verbist J, Peeters P. *What Practical Factors Guide the Choice of Stent and Protection Device during Carotid Angioplasty?* Eur J Vasc Endovasc Surg. 2008 Jun; 35(6):637-43.
60. Bosiers M, Deloose K, Verbist J, Peeters P. *Present and future of endovascular SFA treatments: stents, stent-grafts, drug coated balloons and drug coated stents*. J Cardiovasc Surg (Torino). 2008 Apr;49(2):159-65.
61. Bosiers M, Deloose K, Verbist J, Peeters P. *Does the helical stent structure really prevent stent fractures in the superficial femoral artery?* Greenhalgh et al: 30th Charing Cross Book: Vascular and Endovascular Consensus Update 2008;502-508.
62. Bosiers M, Deloose K, Verbist J, Peeters P. *What should the future stent look like ?* Greenhalgh et al: 30th Charing Cross Book: Vascular and Endovascular Consensus Update 2008;67-76.
63. Bosiers M, Cagiannos C, Deloose K, Verbist J, Peeters P. *Drug eluting stents in the management of peripheral arterial disease*. Vasc Health Risk Manag. 2008;4(3):553-9.
64. Bosiers M, Deloose K, Verbist J, Peeters P. *Why drug-eluting stents may not work for most patients with leg ischemia caused by below-knee arterial occlusive disease*. Vascular Disease Management 2008 Sep/Oct;5(5):140-142.

65. Bosiers M, Deloose K, Verbist J, Peeters P. *Current status of infrapopliteal artery stenting in patients with critical limb ischemia.* J Vasc Bras 2008;7(3):1-8.
66. Bosiers M, Deloose K, Verbist J, Peeters P. *Scoring and Cutting Balloons for SFA Disease Treatment.* Endovascular Today 2008;7(11):34-37.
67. G. de Donato, C. Setacci, K. Deloose, P. Peeters, A. Cremonesi, M. Bosiers. *Long term results of carotid artery stenting.* J Vasc Surg 2008 Oct 9. [Epub ahead of print].
68. Bosiers M, Deloose K, Verbist J, Peeters P. *The impact of embolic protection device and stent design on the outcome of CAS.* Perspect Vasc Surg Endovasc Ther. 2008 Sep;20(3):272-9.
69. Bosiers M, Deloose K, Verbist J, Peeters P. *Technical Challenges and Solutions for the Endovascular Treatment of a Complex Aortoiliac Occlusive Disease.* A. Lobato (Ed.) Endovascular Management of Aorto-Iliac Complications 2008.
70. Cagiannos C, Bosiers M, Deloose K, Verbist J, Peeters P. *The use of the AngioSculpt Scoring Balloon for infrapopliteal lesions in patients with critical limb ischemia: one year outcome.* Vascular 2008, in press.
71. Bosiers M, Lioupis C, Deloose K, Verbist J, Peeters P. *Two-year outcome after Xpert stent implantation for treating "below the knee" lesions in critical limb ischemia.* Vascular 2008, in press.
72. Bosiers M, Peeters P, D'Archambeau O, Hendriks J, Pilger E, Düber C, Zeller T, Gussmann A, Lohle P, Minar E, Scheinert D, Hausegger K, Schulte K, Deloose K, Lammer J. *AMS INSIGHT: Absorbable Metal Stent implantation for treatment of 'below-the-knee' critical limb ischemia: 6-month analysis.* Cardiovasc Intervent Radiol. 2008, in press.
73. Bosiers M, Deloose K, Verbist J, Peeters P. *Carotid stenting is a valuable alternative to carotid endarterectomy.* J Cardiovasc Surg (Torino) 2008 Dec;49(6):709-719.
74. Bosiers M, Deloose K, Peeters P. *Plaque Stability and Carotid Stenting.* MacDonald S., Stansby G. et al, Practical Carotid Artery Stenting. 2008; 81-92.
75. Peeters P, Verbist J, Deloose K, Bosiers M. *Will heparin-bonded PTFE replace autologous venous conduits in infrapopliteal bypass?* J Vasc Endovasc Surg. 2008;15:143-148.
76. Bosiers M, Deloose K, Verbist J, Peeters P. *CAS will prevail on the long run anyway.* Controversies and updates in vascular surgery 2009;7:39-44.
77. Bosiers M, Deloose K, Verbist J, Peeters P. *Update management below knee intervention.* Minerva Cardioangiologica 2009;57:117-129.
78. Bosiers M, Lioupis C, Deloose K, Verbist J, Peeters P. *Two-year outcome after Xpert stent implantation for treating "below the knee" lesions in critical limb ischemia.* Vascular 2009, Jan-Feb;17(1):1-8.
79. Cagiannos C, Bosiers M, Deloose K, Verbist J, Peeters P. *The use of the AngioSculpt Scoring Balloon for infrapopliteal lesions in patients with critical limb ischemia: one year outcome.* Vascular 2009 Jan-Feb;17(1):29-35.
80. Bosiers M, Deloose K. *Femoral bifurcation disease: balloon or knife.* Catheter Cardiovasc Interv. 2009 Apr 13. (Epub ahead of print)
81. Peeters P, Keirse K, Verbist J, Deloose K, Bosiers M. *Other methods of treating the diabetic foot.* J Cardiovasc Surg (Torino). 2009 Jun;50(3):313-321.
82. Bosiers M., Lioupis C, Deloose K., Verbist J, Peeters P. *Classification systems for CLI, chapter 3, Critical Limb Ischemia, Informa Healthcare USA, Inc*
83. Peeters P., Willaert W, Verbist J., Deloose K, Bosiers M., *Endovascular therapy of superficial femoral artery and popliteal lesions in critical limb ischemia, chapter 7, Critical Limb Ischemia, Informa Healthcare USA, Inc*
84. Deloose K., Bosiers M., Verbist J., Peeters P. *Aggressive wound healing strategies, chapter 17, Critical Limb Ischemia, Informa Healthcare USA, Inc*
85. Deloose K, Bosiers M., Peeters P. *One year outcome after primary stenting of infrapopliteal lesions with the CROMIS DEEP stent in the management of critical limb ischemia.* EuroIntervention 2009, Aug;5(3):318-24.
86. Bosiers M, Deloose K, Verbist J, Peeters P. *Drug-eluting superficial femoral artery stents are dead in the water* Greenhalgh et al: 31st Charing Cross Book: Vascular and Endovascular Consensus Update 2009;265-73.
87. Bosiers M, Deloose K, Peeters P. *Selection of protective devices for carotid stenting.* MEET Book 2009
88. Peeters P, Verbert A, Verbist J, Deloose K, Bosiers M. *Vertebral artery angioplasty and stenting.* MEET Book 2009

89. Bosiers M, Deloose K, Verbist J, Peeters P. *CAS will prevail on the long run anyway*. Controversies and updates in vascular surgery 2009;7:39-44.
90. Bosiers M, Lioupis C, Deloose K, Verbist J, Peeters P. *Two-year outcome after Xpert stent implantation for treating "below the knee" lesions in critical limb ischemia*. Vascular 2009, Jan-Feb;17(1):1-8.
91. Bosiers M, Deloose K, Verbist J, Peeters P. *Update management below knee intervention*. Minerva Cardioangiologica 2009;57:117-129.
92. Bosiers M, Deloose K, Cagiannos C, Verbist J, Peeters P. *The use of the AngioSculpt Scoring Balloon for infrapopliteal lesions in patients with critical limb ischemia: one year outcome*. Vascular 2009 Jan-Feb;17(1):29-35.
93. Bosiers M., Lioupis C, Deloose K., Verbist J, Peeters P. *Classification systems for CLI, chapter 3*. Critical Limb Ischemia, Informa Healthcare USA, Inc.
94. Peeters P., Willaert W, Verbist J., Deloose K, Bosiers M., *Endovascular therapy of superficial femoral artery and popliteal lesions in critical limb ischemia, chapter 7*. Critical Limb Ischemia, Informa Healthcare USA, Inc.
95. Deloose K., Bosiers M., Verbist J., Peeters P. *Aggressive wound healing strategies, chapter 17*. Critical Limb Ischemia, Informa Healthcare USA, Inc.
96. Bosiers M, Deloose K, Verbist J, Peeters P. *CAS will prevail on the long run anyway*. Controversies and updates in vascular surgery 2009;7:39-44.
97. Bosiers M, Deloose K, Verbist J, Peeters P. *Drug-eluting superficial femoral artery stents are dead in the water* Greenhalgh et al: 31st Charing Cross Book: Vascular and Endovascular Consensus Update 2009;265-73.
98. Bosiers M, Deloose K, Peeters P. *Selection of protective devices for carotid stenting*. MEET Book 2009; 105-110.
99. Peeters P, Verbert A, Verbist J, Deloose K, Bosiers M. *Vertebral artery angioplasty and stenting*. MEET Book 2009; 185-189.
100. Peeters P, Keirse K, Verbist J, Deloose K, Bosiers M. *Other endovascular methods of treating the diabetic foot*. J Cardiovasc Surg (Torino). 2009 Jun;50(3):313-21. Review.
101. Deloose K, Bosiers M, Peeters P. *One year outcome after primary stenting of infrapopliteal lesions with the Chromis Deep stent in the management of critical limb ischemia*. EuroIntervention 2009 Aug;5(3):318-24.
102. Bosiers M, Deloose K. *Femoral bifurcation disease: balloon or knife*. Catheter Cardiovasc Interv. 2009 Oct 1;74(4):627-33. Review.
103. Bosiers M, Kleinsorge G, Deloose K, Verbist J, Peeters P. *Is thrombolysis useful and possible in a vascular surgery department?* Controversies and updates in vascular surgery 2010 (ISBN 978-88-7711-663-5) Edizioni Minerva Medica S.p.A., Torino, 2010.
104. Bosiers M, Deloose K, Keirse K, Verbist J, Peeters P. *Are drug-eluting stents the future of SFA treatment?* J Cardiovasc Surg (Torino), 2010 Jan;51(1):115-9.
105. Peeters P, Keirse K, Verbist, Deloose K, Bosiers M. *Are bio-absorbable stents the future of SFA treatment?* J Cardiovasc Surg (Torino), 2010 Jan;51(1):121-4.
106. Bosiers M, Deloose K, Peeters P. *Carotid endovascular interventions: patient selection, devices, techniques and tips*. Minerva Cardioangiol. 2010 Feb;58(1):97-111
107. Bosiers M, Deloose K, Vermassen F, Schroë H, Lauwers G, Lansinck W, Peeters P. *The use of the cryoplasty technique in the treatment of infrapopliteal lesions for Critical Limb Ischemia patients in a routine hospital setting: one-year outcome of the Cryoplasty CLIMB Registry*. J Cardiovasc Surg (Torino). 2010 Apr;51(2):193-202.
108. Bosiers M, Lioupis Ch, Deloose K, Verbist J, Peeters P. *Surgical treatment of carotid artery disease*, Haase et al: Cardiovascular Interventions in Clinical Practice. 2010; 596-608
109. Bosiers M, Callaert J, Deloose K, Verbist J, Keirse K, Peeters P. *The role of carotid artery stenting for recent cerebral ischemia*. J Cardiovasc Surg (Torino). 2010 Jun;51(3):293-294.
110. Peeters P, Verbist J, Keirse K, Deloose K, Bosiers M. *Endovascular management of acute limb ischemia*. J Cardiovasc Surg (Torino). 2010 Jun;51(3):329-336
111. Bosiers M, Deloose K, Keirse K, Verbist J, Peeters P. *Prevention and treatment of in-stent restenosis*. J Cardiovasc Surg (Torino). 2010 Aug;51(4):591-598.
112. Hart JP, Bosiers M, Deloose K, Uflacker R, Schönholz CJ. *Impact of stent design on the outcome of intervention for carotid bifurcation stenosis*. J Cardiovasc Surg (Torino). 2010 Dec;51(6):799-806.
113. Bosiers M, Moreels N, Callaert J, Deloose K. *Importance of vascular trainees among centers*. J Cardiovasc Surg (Torino). 2011 Feb;52(1):39-46.

114. Bosiers M, Deloose K, Callaert J, Keirse K, Verbist J, Peeters P. *Drug-eluting stents below the knee*. J Cardiovasc Surg (Torino). 2011 Apr;52(2):231-234.
115. Bosiers M, Deloose K, Callaert J, Moreels N, Keirse K, Verbist J, Peeters P. *One-year results with the Protégé Everflex 200-mm-long nitinol stent (ev3) in TransAtlantic Inter-Society Consensus C and D femoropopliteal lesions: Durability-200 study*. J Vasc Surg. 2011 May 31.
116. Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K, Schmidt A, Tessarek J, Vinck E, Schwartz LB. *Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease*. J Vasc Surg. 2012 Feb;55(2):390-398.
117. Bosiers M, Deloose K, Callaert J, Verbist J, Keirse K, Peeters P. *BRAVISSIMO study: 12-month results from the TASC A/B subgroup*. J Cardiovasc Surg. 2012 Feb;53(1):91-99.
118. Bosiers M, Deloose K. *New developments in diabetic limb salvage*. J Cardiovasc Surg. 2012 Feb;53(1):1-2.
119. Peeters P, Verbist J, Keirse K, Callaert J, Deloose K, Bosiers M. *Endovascular procedures and new insights in diabetic limb salvage*. J Cardiovasc Surg. 2012 Feb;53(1):31-37.
120. Bosiers M, Deloose K, Callaert J, Maene L, Keirse K, Verbist J, Peeters P. *In lower extremity PTAs intraluminal is better than subintimal*. J Cardiovasc Surg. 2012 Apr;53(2):223-227.
121. Bosiers M, Deloose K, Callaert J, Maene L, Keirse K, Verbist J, Peeters P. *Refining stent technologies for femoral interventions*. J Cardiovasc Surg. 2012 Aug;53(4):465-473.
122. Bosiers M, Peeters P, Tessarek J, Deloose K, Strickler S, Zilver PTX Single-Arm Study Investigators. *The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup*. J Cardiovasc Surg. 2013 Feb;54(1):115-122.
123. Deloose K, Lauwers K, Callaert J, Maene L, Keirse K, Verbist J, Peeters P, Bosiers M. *Drug-eluting technologies in femoral artery lesions*. J Cardiovasc Surg. 2013 Apr;54(2):217-224.
124. Bosiers M, Deloose K, Callaert J, Maene L, Beelen R, Keirse K, et al. *BRAVISSIMO: 12-month results from a large scale prospective trial*. J Cardiovasc Surg. 2013 Apr;54(2):235-253.
125. Deloose K. *Bioresorbable Vascular Scaffolds: Progress and Potential*. Endovascular Today. 2013 Feb.
126. Bosiers M, Deloose K, Callaert J, Maene L, Beelen R, Keirse K, et al. *New devices for a better endovascular approach*. J Cardiovasc Surg. 2013 Dec;54(6):713-718.
127. Deloose K. *How and why has your renal stenting practice changed?* Endovascular Today. 2014, August.
128. Deloose K, Bosiers M, Callaert J, Verbist J, Vermassen F, Scheinert D, Torsello G, Peeters P. *Primary stenting is nowadays the golden standard treatment for TASC II A & B iliac lesions: the definitive MISAGO 1-year results*. J Cardiovasc Surg (Torino). 2014 Oct 21.
129. Geiger M, Deloose K, Callaert J, Bosiers M. *Is there already a place for endovascular treatment of the common femoral artery?* J Cardiovasc Surg (Torino). 2015 Feb;56(1):23-9
130. Deloose K. *Endovascular challenges for complex lower extremity lesions?* J Cardiovasc Surg (Torino). 2015 Feb;56(1):19-22.
131. Nasser F, Kambara A, Abath C, Cavalcanti D, Barros I, Pires N, Rivera M, Naser A, Ingrund J, Burihan M, Silveira P, Galego G, Bortoluzzi C, Franklin R, Bosiers M, Deloose K, Razuk A, Caffaro R, Karakhanian WK, Park J, Lopes C, Pinto D, Bez L, Lopes R, Mourão A, Kleinsorge G. *Safety and efficacy of the EPIC™ Nitinol Vascular Stent System for the treatment of lesions located in the Superficial Femoral Artery: prospective and multicentric trial*. J Cardiovasc Surg (Torino). 2015 Mar 3.
132. De Donato G, Bosiers M, Setacci F, Deloose K, Galzerano G, Verbist J, Peeters P, Setacci C. *24-month data from the Bravissimo, a large scale prospective registry on iliac stenting for Tasc A&B and Tasc C&D lesions*. Ann Vasc Surg. 2015 Feb 27. Pii:S0890-5096(15)00132-6
133. Deloose K. *Around the SFA world : Guest Chief Medical Editor Endovascular Today, August 2015, Volume 14, 8*

Books

1. Van Der Bauwhede J, Deloose K. *Introduction in Orthopedic Foot Problems ; Part 2 The Diabetic Foot*. Course Book Institute for Nurse Science, Catholic High School Kortrijk (CATHO), Acco 1996

2. Armando de Carvalho Lobato : Tratamento Endovascular das Complicações aorto-iliacas. Chapter 25 ; ICVE-SP 2008
3. Peter A. Schneider, Marc Bosiers. Critical Limb Ischemia : Chapters 3, 7, 10 and 17. Informa Healthcare 2009.
4. Carlo Setacci. Critical Limb Ischemia : new developments and perspectives. Chapter 21 Edizioni Minerva Medica 2010
5. Abdo Farret Neto : Angiologia para Clinicos : Chapter 9 : Pé Diabético : uma abordagem Multidisciplinar. Rubio Ltda 2012

Lectures

1. Deloose K. *The Diabetic Foot, view point of the vascular surgeon*. Course at the Catholic High School Kortrijk, Department of Nurse science 1996
2. Deloose K, Himpens J, Leman G. *The Dunbar Syndrome, a case history and review of literature*. Symposium General Surgery Dendermonde 1999
3. Deloose K. *Compression Therapy in Vascular Pathology*. National Congress Gymna for Fysiotherapists, Gent 1999
4. Deloose K. *Compression Therapy in Lymphoedema patients*. Post Graduate course for Fysiotherapists, Hasselt 2000
5. Deloose K, Himpens J, Leman G. *Surgical Techniques for The New Millenium*. Ethicon Surgery Forum Vlaanderen. Waasmunster 2000
6. Deloose K, Himpens J, Leman G. *Computer Enhanced Surgery, Robotic surgery and Telesurgery*. Surgical Seminar Catholic University of Leuven, 2000
7. Deloose K. *The Dunbar Syndrome*. Surgical days, University of Antwerp (UIA), 2000
8. Deloose K. *Compression Therapy in Lymphoedema patients*. Post Graduate course for Fysiotherapists, Hasselt 2001
9. Deloose K. *Compression Therapy in Vascular Pathology*. National Congress Gymna for Fysiotherapists, Gent 2001
10. Deloose K. *Compression Therapy in Lymphoedema patients*. Post Graduate course for Fysiotherapists, Hasselt 2002
11. Deloose K, Peeters P, Bosiers M. *Carotid procedure from a vascular surgeon's point of view*. Vascular Endovascular Interventions Techniques Horizons, New York, November 2002.
12. Deloose K, Bosiers M, Peeters P. *Why implement a carotid angioplasty program in a center with experience in carotid endarterectomy*. Belgian Surgical Week, Ostend, May 2003.
13. Deloose K, Bosiers M, Peeters P. *Belgian Carotid Experience*. Yearly meeting of the Norwegian society of Vascular Surgery, Bergen, March 2004.
14. Deloose K, Bosiers M, Peeters P. *Endovascular Treatment Strategy for Below Knee Pathology in Patients with CLI*. Yearly meeting of the Norwegian society of Vascular Surgery, Bergen, March 2004.
15. Deloose K, Bosiers M, Peeters P. *Preliminary results of the bioabsorbable magnesium stents (FIM)*. Interventional Radiology Meeting, Lisbon, March 2004.
16. Deloose K, Bosiers M, Peeters P. *Guidelines and musts on how to start a carotid stent program*. BSCI symposium, Ravenna, June 2004.
17. Deloose K, Bosiers M, Peeters P. *Are biodegradable stents the answer? First results in human SFA/tibial vessels*. ISET, Miami, January 2005.
18. Deloose K, Bosiers M, Peeters P. *Excimer laser for tibial disease*. ISET, Miami, January 2005.
19. Deloose K, Bosiers M, Peeters P. *12 month FU results with the AMS in below the knee indications*. Biotronik symposium, Lissabon, April 2005.
20. Deloose K, Bosiers M, Peeters P. *How do I perform Infrapopliteal occlusion with AMS*. CICE, Sao Paulo, April-May 2005.
21. Deloose K, Bosiers M, Peeters P. *Renal stenting: Avoiding and managing complications*. CICE, Sao Paulo, April-May 2005.
22. Deloose K, Bosiers M, Peeters P. *Excimer laser ablation: have we found a solution for long infrapopliteal lesions*. CICE, Sao Paulo, April-May 2005.

23. Deloose K, Bosiers M, Peeters P. *CLI: Preliminary results for AMS*. CICE, Sao Paolo, April-May 2005.
24. Deloose K, Bosiers M, Peeters P. *Endovascular strategies for BTK interventions*. Abbott round Table-meeting (ART), Copenhagen, October 2005.
25. Deloose K, Bosiers M, Peeters P. *Role of Vascular interventions in PAD – are TASC recommendations useful ?*. 6th ISCVI, Kitzbühel, Austria, Februari 2006.
26. Deloose K, Bosiers M, Peeters P. *Guidelines and musts on how to start a carotid stent program*. Carotid Stenting Workshop, Hong Kong, March 2006..
27. Deloose K, Bosiers M, Peeters P. *A Correção Endovascular É Alternativa Válida à Cirurgia em Pacientes com Isquemia Crítica de MMII: Análise Custo-Benefício*. CICE, Sao Paolo, April 2006
28. Deloose K, Bosiers M, Peeters P. *Stent Venoso: Um Tópico Negligenciado na Cirurgia Endovascular?*. CICE, Sao Paolo, April 2006
29. Deloose K, Bosiers M, Peeters P. *Stent Carotídeo: Será que Funciona Mesmo a Longo Prazo? Resultados do Estudo ELOCAS*. CICE, Sao Paolo, April 2006
30. Deloose K, Bosiers M, Peeters P. *Será Que Temos os Stents Adequados para as Lesões Fêmoro-Poplíteas?* CICE, Sao Paolo, April 2006
31. Deloose K, Bosiers M, Peeters P. *Clinical Results with Absorbable Magnesium Stents*. Biotronik symposium, Kopenhagen, May 2006.
32. Deloose K, Bosiers M, Peeters P. *Will bioabsorbable technology revolutionise our endovascular approach?* 15th JSCI, Fukuoka, June 2006.
33. Deloose K, Bosiers M, Peeters P. *Do we have the right endovascular tools for BTK-pathology?* 15th JSCI, Fukuoka, June 2006.
34. Deloose K, Bosiers M, Peeters P. *Hot topics in carotids*. 15th JSCI, Fukuoka, June 2006.
35. Deloose K, Bosiers M, Peeters P. *Biodegradable stents*. The 6th international symposium of cardiovascular and interventional radiology, Moscou, December 2006.
36. Deloose K, Bosiers M, Peeters P. *Angioplasty for below the knee arteries*. The 6th international symposium of cardiovascular and interventional radiology, Moscou, December 2006.
37. Deloose K, Bosiers M, Peeters P. *CAS: Is Outcome Dependent on Device Characteristics?* ISET, Miami, January 2007.
38. Deloose K, Bosiers M, Peeters P. *CAS: AMS - Insight I: Six-month Results of PTA vs. Bioabsorbable Stents*. ISET, Miami, January 2007.
39. Deloose K, Bosiers M, Peeters P. *Long-term Outcomes of the Xpert Below the Knee Study*. ISET, Miami, January 2007.
40. Deloose K, Bosiers M, Peeters P. *CAS: Long-term Outcomes of the Xpert Below the Knee Study*. ISET, Miami, January 2007.
41. Deloose K, Bosiers M, Peeters P. *What is the ideal stent to treat infrapopliteal lesions?* CICE, Sao Paolo, April 2007.
42. Deloose K, Bosiers M, Peeters P. *Carotid Stenting: Do device characteristics impact outcome in carotid artery stenting?* CICE, Sao Paolo, April 2007
43. Deloose K, Bosiers M, Peeters P. *Critical Limb Ischemia: BTK trials stenting vs PTA*. AIWES 14th International Workshop, Ajaccio, June 2007.
44. Deloose K, Bosiers M, Peeters P. *Does the type of embolic protection influence outcome in carotid artery stenting?* CIRSE, Athens, September 2007.
45. Deloose K, Bosiers M, Peeters P. *Case presentation at ev3 Learning Session*. CIRSE, Athens, September 2007.
46. Deloose K, Bosiers M, Peeters P. *Endovascular results for iliac intervention*. ICEP, Rome, September 2007.
47. Deloose K, Bosiers M, Peeters P. *Traitement endovasculaire des artères jambières : Souvent en beaucoup de stents*. ACVB – Perspectives 2007, Bordeaux, December 2007.
48. Deloose K, Bosiers M, Peeters P. *Limb salvage after stenting*. Diabetic Foot Meeting, Milan, February 2008.
49. Deloose K, Bosiers M, Peeters P. *Critical Limb Ischemia : Endovascular versus surgical treatment*. Belgian Surgical Week, Ostend, May 2008.
50. Deloose K, Bosiers M, Peeters P. *Best treatment options – a clinical perspective*. DFWG, Johannesburg, June 2008.
51. Deloose K, Bosiers M, Peeters P. *Clinical literature review: The Diabetic foot*. DFWG, Johannesburg, June 2008.

52. Deloose K, Bosiers M, Peeters P. BTK-treatment : endovascular strategy. AIWES 15th International Workshop, Ajaccio, June 2008.
53. Deloose K, Bosiers M. Two-year outcome after Xpert stent implantation for treating "below the knee" lesions in critical limb ischemia. ESVS, Nice, September 2008.
54. Deloose K, Bosiers M. Limb salvage in the diabetic patient: which endovascular technique to use ? ICEP, Rome, October 2008.
55. Deloose K, Bosiers M. Aorto-iliac occlusive disease: Does the TASC-II recommendations reflect our daily practice? IX Encontro de Angiologia e Cirurgia Vascular do Cone Sul, Porto Alegre, October 2008.
56. Deloose K, Bosiers M. Why vascular surgeons should treat patients with Critical Limb Ischemia? IX Encontro de Angiologia e Cirurgia Vascular do Cone Sul, Porto Alegre, October 2008.
57. Deloose K, Bosiers M. For CAS which stent and which protection system should we use and why: Which lesion should not be treated? IX Encontro de Angiologia e Cirurgia Vascular do Cone Sul, Porto Alegre, October 2008.
58. Deloose K, Bosiers M. Endovascular below-the-knee strategies. IX Encontro de Angiologia e Cirurgia Vascular do Cone Sul, Porto Alegre, October 2008.
59. Deloose K, Bosiers M. 12-Month Results With The Lifestent (Bard) For Popliteal Lesions. VEITH, New York, November 2008.
60. Deloose K, Bosiers M. Stent Characteristics And Geometry Are Of Critical Importance In The Outcome Of CAS: Is There Better Stent Technology On The Horizon? VEITH, New York, November 2008.
61. Deloose K, Bosiers M. Evolution Of Optimal Below-Knee Stents: Randomized Controlled Trial Of Absorbable Metal Stents vs. Bare Metal Stents For Critical Ischemia Due To Below-the-Knee Lesions. VEITH, New York, November 2008.
62. Deloose K, Bosiers M. 4-year patency. VEITH, New York, November 2008.
63. Deloose K, Bosiers M. Endovascular Strategy for CLI patients : Marathon endovascular. Sao Paulo, Brazil, December 2008.
64. Deloose K, Bosiers M. The renal artery stenting paradigm : Marathon endovascular. Sao Paulo, Brazil, December 2008.
65. Deloose K, Bosiers M. *Below the knee angioplasty: dilatation, stenting and other techniques*. Ischemic Diabetic Foot Treatment, March 2009
66. Deloose K, Bosiers M. *Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia – in diabetic patients*. VII Encontro Sao Paulo de Cirurgia Vascular, April 2009..
67. Deloose K, Bosiers M. *EVAR. Preserving the pelvic circulation. Sense or non-sense?* Ajaccio, June 2009.
68. Deloose K, Bosiers M. *O futuro do tratamento endovascular das lesões ateroscleróticas da artéria femoral superficial*. SOBRICE, Sao Paulo, November 2009.
69. Deloose K, Bosiers M. *Tratamento endovascular de lesões ateroscleróticas abaixo de joelho: como estamos agora?* SOBRICE, Sao Paulo, November 2009.
70. Deloose K, Bosiers M. *"O céu e o limite": Tratamento das lesões ilíaco-femorais TASC II*, SOBRICE, Sao Paulo, November 2009.
71. Deloose K, Bosiers M. *Quando indicar o tratamento endovascular na doença carotídea aterosclerótica?*, SOBRICE, Sao Paulo, November 2009.
72. Deloose K, Bosiers M. *Selection of carotid stents: does it really matter and why?* Pan American Congress (Endopan), Rio de Janeiro, November 2009
73. Deloose K, Bosiers M. *The challenge of managing upper extremity vascular disease*. Pan American Congress (Endopan), Rio de Janeiro, November 2009
74. Deloose K, Bosiers M. *Update TASC 2: Can we extend endovascular treatment to C and D lesions?* ETI, Siena, March 2010.
75. Deloose K, Bosiers M. *Carotid stent design: current status and future perspectives*. ETI, Siena, March 2010.
76. Deloose K, Bosiers M. *Drug eluting stent vs. bare metal stents to treat below-knee lesions*. ETI, Siena, March 2010.
77. Deloose K, Bosiers M. *What is my diagnostic protocol for carotid stenosis?* XV Encontro Pernambucano, Recife, May 2010.
78. Deloose K, Bosiers M. *Carotid endovascular surgery: do new stents produce different results?* XV Encontro Pernambucano, Recife, May 2010.

79. Deloose K, Bosiers M. *What is my surveillance protocol for endovascular treatment?* XV Encontro Pernambucano, Recife, May 2010.
80. Deloose K, Bosiers M. *Limb salvage techniques for critical ischemia: an expert opinion.* XV Encontro Pernambucano, Recife, May 2010.
81. Deloose K, Bosiers M. *A classificação Task e a melhor norteadora da indicação do tipo de cirurgia?* XI Encontro Mineiro de Angiologia e Cirurgia Vasculard, Divinópolis, June 2010.
82. Deloose K, Bosiers M. *Aneurismas de artéria poplítea, convencional ou endovascular.* XI Encontro Mineiro de Angiologia e Cirurgia Vasculard, Divinópolis, June 2010.
83. Deloose K, Bosiers M. *Quais os melhores resultados em Isquemia Crítica: cirurgia convencional ou endovascular.* XI Encontro Mineiro de Angiologia e Cirurgia Vasculard, Divinópolis, June 2010.
84. Deloose K, Bosiers M. *Necessário filtro de proteção no tratamento endovascular da origem das artérias carótidas? Quais e qual o melhor filtro de proteção na ATP de artéria carótida?* XI Encontro Mineiro de Angiologia e Cirurgia Vasculard, Divinópolis, June 2010.
85. Deloose K. *Embolização de fibromas uterinas.* Centro de Estudos Hospital Felício Rocho, Belo Horizonte, Brazil ; April 18th 2011.
86. Deloose K. *Iliac lesions : which stent for which lesion : first bravissimo results.* CICE, WTC Sao Paolo, Brazil. April 21th 2011.
87. Deloose K. *Simulation is a waste of time: all training should be patient based.* VEITH, New York, November 19th 2011.
88. Deloose K. *Closed-cell stents decrease cerebral embolization.* VEITH, New York, November 20th 2011.
89. Deloose K. *Overview of materials and devices used during endovascular procedures in the BTK area.* Capitulo Cirurgia Endovascular, Madrid, December 2011.
90. Deloose K. *Endoluminal SFA bypasss for the treatment of In-Stent Restenosis: the RELINE trial.* Capitulo Cirurgia Endovascular, Madrid, December 2011.
91. Deloose K. *Popliteal case.* BEC, Sophia, December 2011.
92. Deloose K. *BTK case.* BEC, Sophia, December 2011.
93. Deloose K. *ABSORB-BTK cases.* LINC, Leipzig, January 24th 2012.
94. Deloose K. *4F in practice: lessons from 4EVER.* LINC, Leipzig, January 24th 2012.
95. Deloose K. *VIVA@LINC: Complication case.* LINC, Leipzig, January 24th 2012.
96. Deloose K. *How to present/discuss the 4EVER data with your physicians.* LINC, Leipzig, January 25th 2012.
97. Deloose K. *4EVER Study: 6-month results.* CICE, Sao Paulo, April 26th 2012.
98. Deloose K. *Are SFA long lesions (TASC C/D) best treated with endovascular repair?* CICE, Sao Paulo, April 26th 2012.
99. Deloose K. *Drug eluting bio-absorbable stents: is it the new frontier?* Annual Innovations in Complex Vascular & Endovascular Interventions, New York, May 10th 2012.
100. Deloose K. *Drug coated balloon therapy: outcomes from Europe & clinical trials.* Annual Innovations in Complex Vascular & Endovascular Interventions, New York, May 10th 2012.
101. Deloose K. *BRAVISSIMO: 12-month results from a large scale prospective trial.* EVS, Pittsburgh, September 14th 2012.
102. Deloose K. *The ASTI trial: 30-day primary endpoint results with carotid artery stenting under distal protection in surgical high-risk patients.* EVS, Pittsburgh, September 15th 2012.
103. Deloose K. *In-stent restenosis case: endoluminal SFA byass for the treatment of SFA in-stent restenosis: what does the RELINE trial indicate?* CIRSE, Lissabon, September 17th 2012.
104. Deloose K. *Long term data: real life experience of endovascular first approach in TASC C and D patients and 2 year BRAVISSIMO TASC A and B data.* CIRSE, Lissabon, September 17th 2012.
105. Deloose K. *4EVER study 12 month data – practical implications.* CIRSE, Lissabon, September 18th 2012.
106. Deloose K. *How to interpret 4EVER 12 month results to discuss with physicians.* CIRSE, Lissabon, September 18th 2012.
107. Deloose K. *Bioresorbable vascular scaffolds: hope or hype?* VIVA, Las Vegas, October 11th 2012.

108. Deloose K. *LINC@VIVA: The challenge of long SFA lesions – what is the best practice?* VIVA, Las Vegas, October 11th 2012.
109. Deloose K. *The ASTI-trial: 30 day results of the new Adapt stent in the treatment of high risk surgical patients.* PAN, Barra da Tijuca, October 31st 2012.
110. Deloose K. *Are SFA long lesions (TASC C/D) best treated with endovascular repair?* PAN, Barra da Tijuca, November 2nd 2012.
111. Deloose K. *Future of bioabsorbable stent technology in infrainguinal pathology.* PAN, Barra da Tijuca, November 2nd 2012.
112. Deloose K. *Use of 4Fr systems for treating fem-pop lesions: advantages and disadvantages: lessons from the 4EVER trial using Astron Pulsar stents and no closure devices.* VEITH, New York, November 15th 2012.
113. Deloose K. *Real life experience of endovascular first approach in TASC C and D patients after BRAVISSIMO.* BEC, Sophia, December 16th 2012.
114. Deloose K. *Technologies for the future: resorbable stents ABSORB BTK and ESPRIT.* BEC, Sophia, December 16th 2012.
115. Deloose K. *4EVER results.* BEC, Sophia, December 16th 2012.
116. Deloose K. *Endovascular approach of iliacs works in all TASC lesions.* BEC, Sophia, December 16th 2012.
117. Deloose K. *Complex cases in iliac and SFA.* LINC, Leipzig, January 23rd 2013.
118. Deloose K. *4EVER 12 months data – practical implications.* LINC, Leipzig, January 24th 2013.
119. Deloose K. *Real life experience and longer term data in iliac stenting BRAVISSIMO TASC C&D 2 year data.* LINC, Leipzig, January 25th 2013.
120. Deloose K. *Subintimal or intraluminal, which way to go?* LINC, Leipzig, January 25th 2013.
121. Deloose K. *Body of evidence for drug eluting stents below the knee – DESTINY, YUKON and ACHILLES trials.* Charing Cross, London, April 6th 2013.
122. Deloose K. *Gore Viabahn Endoprosthesis for In-Stent Restenosis.* Charing Cross, London, April 7th 2013.
123. Deloose K. *Making the right choice in BTK: DEB vs. DES vs. atherectomy vs. POBA.* CICE, Sao Paulo, April 24th 2013.
124. Deloose K. *PULSAR-LUX: Combination strategy of nitinol stent and DEB.* CICE, Sao Paulo, April 25th 2013.
125. Deloose K. *CTO Angioplasty/Stenting with Passeo balloon and Pulsar 18 stent.* CICE, Sao Paulo, April 26th 2013.
126. Deloose K. *Results of drug coated trials in Europe and USA – Is it a game changers?* Annual Innovations & Controversies in Complex Vascular Interventions & Wound Management, New York, May 9th 2013.
127. Deloose K. *Stem cell therapy for unreconstructable CLI.* Annual Innovations & Controversies in Complex Vascular Interventions & Wound Management, New York, May 9th 2013.
128. Deloose K. *Bioabsorbable stents: is this the future?* Annual Innovations & Controversies in Complex Vascular Interventions & Wound Management, New York, May 10th 2013.
129. Deloose K. *Futuro da tecnologia absorvível nas lesões periféricas.* TOPE International Meeting, Recife, September 5th 2013.
130. Deloose K. *Evidência clínica no tratamento das lesões infrapatelares.* TOPE International Meeting, Recife, September 5th 2013.
131. Deloose K. *O futuro do stent carotídeo.* TOPE International Meeting, Recife, September 5th 2013.
132. Deloose K. *A stepwise approach to managing SFA, popliteal and tibial chronic total occlusions – optimizing today's technology and techniques.* SBACV Congress, Florianópolis, October 1st 2013.
133. Deloose K. *In-stent restenosis – when should we consider endovascular vs. surgical revascularization options.* SBACV Congress, Florianópolis, October 1st 2013.
134. Deloose K. *Bioresorbable vascular scaffold in BTK lesions: is this science fiction?* SBACV Congress, Florianópolis, October 3rd 2013.
135. Deloose K. *PULSAR-LUX: A combined strategy; Nitinol stents and drug eluting balloons.* SBACV Congress, Florianópolis, October 3rd 2013.

136. Deloose K. *Less invasive interventions with 4F systems like the Astron Pulsar stent: the 4EVER trial Final results: Closure devices are not needed.* VEITH, New York, November 20th 2013.
137. Deloose K. *BTK strategy.* VEITH, New York, November 20th 2013.
138. Deloose K. *Tack Optimized Plain Balloon Angioplasty: Will it replace stenting – the Tack-It device: How does it work and the TOBA trial.* VEITH, New York, November 20th 2013.
139. Deloose K. *When should CLI patients be treated with a bypass: an endovascularly oriented surgeon's view.* VEITH, New York, November 20th 2013.
140. Deloose K. *What's new in DES for Fem-Pop and BTK lesions: Results of the Destiny 2 and PES BTK-70 trials with Paclitaxel and Everolimus Eluting Stents.* VEITH, New York, November 22nd 2013.
141. Deloose K. *Technical aspect for covered stent in the aorto-iliac area (sizing et technique du stenting couvert aorto-iliaque), PERSPECTIVES, Bordeaux, December 13th 2013.*
142. Deloose K. *Critical Limb Ischemia : Endovascular is the first choice strategy.* CACVS, Paris, January 23rd – 25th 2014.
143. Deloose K. *The 4EVER : Final 24 months results.* LINC, Leipzig, January 28th – 31st 2014.
144. Deloose K. *Subintimal or intraluminal – which way to go?* LINC, Leipzig, January 28th – 31st 2014.
145. Deloose K. *The Reline trial: randomized clinical trial : Viabahn covered stents vs PTA .* LINC, Leipzig, January 28th – 31st 2014.
146. Deloose K. *DESTINY 2 study: preliminary 6-month results.* BEC, Sofia, February 23rd 2014
147. Deloose K. *Open surgical vs endovascular treatment of iliac cases.* BEC, Sofia, February 23rd 2014
148. Deloose K. *RELIN Study – preliminary 24-month results.* BEC, Sofia, February 23rd 2014
149. Deloose K. *How good is the benchmark? Performance of latest generation nitinol stents and DES.* CICE, Sao Paulo, April 23rd 2014.
150. Deloose K. *Less is more in the SFA: 4EVER 24-month results.* CICE, Sao Paulo, April 24th 2014.
151. Deloose K. *Clinical evidence in SFA/Popliteal.* GREAT MINDS, Berlin, May 13th 2014.
152. Deloose K. *DES & BVS experience in BTK*
153. Deloose K. *Debate : Drug coated balloons are dangerous in CLI. How about PTA or atherectomy with bailout DES when needed.* MEET, Nice, October 10th 2014.
154. Deloose K. *Dedicated, self-expanding, drug-eluting stent for the BTK arteries – The Stentys device and 6 month trial results.* MEET, Nice, October 10th 2014.
155. Deloose K. *These are the trials that need to be doen to advance CLI.* MEET, Nice, October 10th 2014.
156. Deloose K. *Evidence for endovascular treatment for TASC C and D femoral lesions.* MEET, Nice, October 10th 2014.
157. Deloose K. *Biolux P-II: A randomized clinical trial of Passeo-18 LUX DRB vs POBA for the treatment of infrapopliteal artery lesions.* CIRSE, Glasgow, September 13th 2014.
158. Deloose K. *Clinical Evidence for Roadsaver Carotid Stent : the CLEAR-ROAD trial.* CIRSE, Glasgow, September 13th 2014.
159. Deloose K. *Pulsar Data – Radial forces and the link to clinical data.* CIRSE, Glasgow, September 13th 2014.
160. Deloose K. *Guidewire, ballon and catheter selection for the treatment of PAOD.* CONESUL, Gramado, October 3rd, 2014.
161. Deloose K. *Resorbable stent technology – the peripheral area.* CONESUL, Gramado, October 3rd, 2014.
162. Deloose K. *Drug-eluting balloons and drug-eluting stents in infrapopliteal disease.* CONESUL, Gramado, October 3rd, 2014.
163. Deloose K. *Endovascular treatment for complex aorta-iliac lesions and covered stents in aorto-iliac disease.* CONESUL, Gramado, October 4th, 2014.
164. Deloose K. *Nitinol stents still are the first choice for the majority of SFA lesions.* CONESUL, Gramado, October 4th, 2014.
165. Deloose K. *Stent-grafts, drug-eluting stents and drug-eluting balloons in the SFA,* CONESUL, Gramado, October 4th, 2014.

166. Deloose K, *Status of modern endovascular therapies in claudicants; an evidence appraisal*. Medtronic Faculty Education Program, Istanbul, October 18th, 2014.
167. Deloose K, *In.Pact clinical performances in real world population*, CACVS, Paris, January 23rd 2015.
168. Deloose K, *Controversy : Extreme Endovascular?* CACVS, Paris, January 24th 2015.
169. Deloose K, *DES*, CACVS, Paris, January 24th 2015.
170. Deloose K, *Does stent design influence the results of SFA stenting?* LINC, Leipzig, January 29th 2015.
171. Deloose K. *Proven? Combining DEB and stent*. LINC, Leipzig, January 29th 2015.
172. Deloose K. *Subintimal or intraluminal, which way to go?* LINC, Leipzig, January 29th 2015.
173. Deloose K. *Clinical evidence for RoadSaver carotid stent – the CLEAR-ROAD trial*. LINC, Leipzig, January 29th 2015.
174. Deloose K. *Understanding Radial Force: What does it mean?* LINC Asia-Pacific, March 9th 2015, Hong Kong, China
175. Deloose K. *European experience on ZILVER-PTX*. LINC Asia-Pacific, March 9th 2015.
176. Deloose K. *Crossing difficult lesions: recanalization/reentry tools and techniques Below-the-Knee*. LINC Asia-Pacific, March 9th 2015, Hong Kong, China
177. Deloose K. *Destiny II: 12 months results with long segment DES treatment in BTK arteries*. LINC Asia-Pacific, March 10th 2015, Hong Kong, China
178. Deloose K. *Treatment modalities for TASC C and D femoropopliteal lesions: a review of evidence*. LINC Asia-Pacific, March 10th 2015, Hong Kong, China
179. Deloose K. *Flash presentation: Current solutions for in-stent-restenosis*. LINC Asia-Pacific, March 10th 2015, Hong Kong, China
180. Deloose K. *Carotid stenting in 2015 requires advanced imaging tools*. Charing Cross, April 30th 2015, London, UK
181. Deloose K. *When advanced imaging enters the field of complex lower limb disease management*. Charing Cross, April 30th 2015, London, UK
182. Deloose K. *Carotid Stents : open cell, closed cell, micromesh, new concepts*. European Society for Vascular Medicine 2015, Potsdam, Germany, May 10th 2015.
183. Deloose K. *Hands-on catheter material and simulator training*. European Society for Vascular Medicine 2015, Potsdam, Germany, May 10th 2015.
184. Deloose K. *The Future of Endovascular Peripheral Technology*. ISES Worldwide Celebration Congress, Paris, France. May 22th 2015.
185. Deloose K. *Latest peripheral endovascular technologies*. ISES Worldwide Celebration Congress, Paris, France. May 22th 2015.
186. Deloose K. *State of the art of BTK-CLI treatment*. MEET congress 2015, Nice, France, June 8th 2015
187. Deloose K. *Antiplatelet therapy : who needs it and what to prescribe?* MEET congress 2015, Nice, France, June 8th 2015
188. Deloose K. *Tips and Tricks for the CERAB technique*. MEET congress 2015, Nice, France, June 9th 2015
189. Deloose K. *Why and When do I use mimetic stents?* SITE congress 2015, Barcelona, Spain, June 25th 2015
190. Deloose K. *When and How should we treat in-stent restenosis?* SITE congress 2015, Barcelona, Spain, June 25th 2015
191. Deloose K. *SFA : new technologies mean new issues*. SITE congress 2015, Barcelona, Spain, June 25th 2015
192. Deloose K. *Stent design : a pioneering scientific viewpoint on radial force*. CIRSE 2015, Lisbon, Portugal, September 29th 2015
193. Deloose K. *Clinical outcomes of the Bioflex-I study : utilization of self-expanding stents in the iliac arteries*. CIRSE 2015, Lisbon, Portugal, September 29th 2015

Congress Involvement

1. Bosiers M, Deloose K. *Organisation of Symposium "New Trends in Vascular Surgery"*. Dendermonde, January 2002.
2. Bosiers M, Peeters P, Deloose K, Verbist J. *Live Case from Bonheiden*. Paris Course on Revascularisation, Paris, May 2002.
3. Bosiers M, Deloose K. *Organisation of Symposium "Vaatlijden in de Huisartsenpraktijk [Vascular pathology for the general practitioner]"*. Dendermonde, January 2003.
4. Bosiers M, Deloose K. *Organisation of Symposium "Vasculair High-Tech Symposium"*. Sint-Niklaas, January 2004.
5. Bosiers M, Deloose K. *Organisation: "Hands-on carotid training"*. ICCA, Frankfurt, October 2004.
6. Bosiers M, Deloose K. *Organisation of Symposium "VIU05 – Multidisciplinaire samenwerking in de Vaculaire Interventie Unit"*. Buggenhout, January 2005.
7. Deloose K. *Performance Live Case*. CICE, Sao Paolo, April-May 2005.
8. Deloose K. *Organisation of Symposium "VIU06 – VIU in motion"*. Zaffelaere, February 2006.
9. Deloose K. *Performance Live Case*. CICE, Sao Paolo, April 2006.
10. Bosiers M, Deloose K. *Organisation of Symposium "VIU07 – VIU Back to Basics"*. Londerzeel, February 2007.
11. Bosiers M, Deloose K. *Organisation of Symposium "VIU08 – Q&A"*. Lebbeke, February 2008.
12. Deloose K. *Performance Live Cases*. Sao Paolo, May 2008.
13. Deloose K. *Performance Live Cases*. Fortaleza, July 2008.
14. Deloose K. *Performance Live Cases*. Joinville/Blumeneau/Curitiba/Porto Alegre, October 2008.
15. Deloose K. *Performance Live Cases*. Sao Paolo, December 2008.
16. Deloose K. *Performance Live Cases*. HC/Unicamp Hospital, Campinas, March 2009
17. Deloose K. *Performance Live Cases*. UNESP Hospital, Botucatu, March 2009
18. Deloose K. *Performance Live Cases*. UNIFESP/EPM Hospital, Sao Paulo, April 2009
19. Deloose K. *Performance Live Cases*. HC/USP Hospital, Sao Paulo, April 2009
20. Deloose K. *Moderator: Management of Diabetic Foot problems*. VII Encontro Sao Paulo de Cirurgia Vascular, April 2009.
21. Deloose K. *Moderator: Arterial Disease*. VII Encontro Sao Paulo de Cirurgia Vascular, April 2009.
22. Deloose K. *Moderator: Critical Limb Ischemia*. VII Encontro Sao Paulo de Cirurgia Vascular, April 2009.
23. Deloose K. *Commentator during live case from Udine*. ETI, Siena, March 2010.
24. Deloose K. *Moderator session challenging lesions workshop*. LINC January 20th 2011, Leipzig
25. Deloose K. *Performance Live Case*. CICE, Sao Paolo, April 2011.
26. Deloose K. *Performance Live Case*. CICE, Sao Paolo, April 2012.
27. Deloose K. *Live Case Panelist*, VIVA, Las Vegas, October 2012.
28. Deloose K. *Moderator: Superficial Femoral Artery Treatment*. BEC, Sophia, December 16th 2012.
29. Deloose K. *Chairman: Pulsar and beyond – can we do better?* LINC, Leipzig, January 24th 2013.
30. Deloose K. *Chairman: Evolution and revolution in iliac and SFA technology*. LINC, Leipzig, January 25th 2013.
31. Deloose K. *Chairman: Access strategies and tools for crossing complex femoropopliteal and BTK lesions*. LINC, Leipzig, January 25th 2013.
32. Deloose K. *Performance Live Case*. CICE, Sao Paulo, April 26th 2013.
33. Deloose K. *Moderator: Recanalização Femoro-poplíteia 2*. TOPE, Recife, September 5th 2013.
34. Deloose K. *Moderator: Stent carotídeo*. TOPE, Recife, September 5th 2013.
35. Deloose K. *Moderator: Isquemia cerebrovascular*. TOPE, Recife, September 5th 2013.
36. Deloose K. *Panelist: 3 complex CLI case presentations with panel discussion*. SBACV, Florianópolis, October 1st 2013.
37. Deloose K. *Moderator: European Session CTO – BTK*. SBACV, Florianópolis, October 3rd 2013.

38. Deloose K. *Performance Live Cases*. LINC, Leipzig, January 28th 2014. (member of Live Case Committee)
39. Deloose K. *Moderator: What should you leave behind? Stent or drug?* LINC, Leipzig, January 29th 2014
40. Deloose K. *Performance Live Cases*. LINC, Leipzig, January 29th 2014. (member of Live Case Committee)
41. Deloose K. *Moderator: LINC Expert Course : Advanced techniques for critical limb ischemia part I*. LINC, Leipzig, January 30th 2014.
42. Deloose K. *Moderator: Below The Knee (BTK)*. BEC, Sofia, February 23rd 2014.
43. Deloose K. *Panellist: Unsolved issues in lower limb endo-revascularization: from the lacking evidence up to the durability concerns*
44. Deloose K. *Performance Live Cases*. LINC, Leipzig, January 28th, 2015. (member of Live Case Committee)
45. Deloose K. *Performance Live Cases*. LINC, Leipzig, January 29th, 2015. ((member of Live Case Committee))
46. Deloose K. *Moderator: The next frontier: Interventional treatment for deep venous thrombosis*. LINC Asia-Pacific, March 9th, 2015.
47. Deloose K. *Moderator : The next frontier: Interventional treatment for deep venous thrombosis*. LINC Asia-Pacific, March 9th 2015.
48. Deloose K. *Moderator : Symposium: Drug eluting technologies: the final 5 years results*. LINC Asia-Pacific, March 9th 2015.
49. Deloose K. *Moderator : Scrub in with experts: the retrograde transpedal approach in critical limb ischemia*, LINC Asia-Pacific, March 9th 2015.
50. Deloose K. *Moderator : Critical Limb Ischemia treatment 2015*. LINC Asia-Pacific, March 10th 2015.
51. Deloose K. *Performance Live Cases*. CICE, Sao Paolo, April 29th, 2015.
52. Deloose K. *Performance Live Cases*. CICE, Sao Paolo, April 30th, 2015.

Editorial Boards

1. 2014: Member of the Editorial Advisory Board – Endovascular Today
2. 2015 : Editorial Board – Journal of Cardiovascular Surgery – Endovascular Section

Proctoring & Consultancy

3. Carotid stenting procedures world-wide for Boston Scientific
4. Teacher at Institute for Therapy Advancement, Villepinte, France ; Boston Scientific
5. Critical Limb Ischemia procedures worldwide for Biotronik
6. Teacher and proctor for Abbott Vascular
7. Teacher and proctor for Cook Medical
8. Teacher and proctor for Medtronic-Invatec
9. Teacher endovascular animal training, Medanex, Diest (Belgium)